Oura agrees to buy AI care practice Counsel Health
Also in this issue: LifeMD delays its 10-Q to fix revenue
Forwarded this? Get it weekday mornings.
Take. Oura, a ring company with six million paying members, is buying a practice that can prescribe inside its app. Cash-pay longevity and hormone clinics buy ads to find those same health-curious patients. Oura already has them, along with their sleep and heart data. Expect patients who start on a wearable to get harder and more expensive to win. We'd move budget toward referrals and toward keeping the patients a clinic already has.
Oura, the smart-ring maker, signed a definitive agreement to acquire Counsel Health, per Oura's announcement Tuesday. Counsel runs a medical AI supervised by board-certified physicians. Its doctors can order labs and prescribe inside the Oura app. Oura and Counsel have worked together since May. Oura expects the deal to close near the end of this year.
Reuters reports the price at $625 million in cash. Oura's post doesn't give one. TechCrunch says the deal comes weeks after Oura postponed its IPO. The companies plan to expand into specialty and chronic care. Counsel will keep selling to health plans and health systems.
The pitch to investors rests on staffing. Counsel's first financial backer, Asymmetric Capital Partners, says AI lets one Counsel physician care for more than 25,000 members. It puts a traditional primary care doctor at roughly 1,500. That ratio is the backer's claim.
Oura's own example is a 68-year-old member who asked Counsel about her scheduled GLP-1 injection after food poisoning. The announcement doesn't say whether Counsel prescribes GLP-1s.
Money
LifeMD delays its quarterly report to fix overstated revenue
LifeMD, a public cash-pay telehealth company, told the SEC Monday it can't file its third-quarter 10-Q on time. It must correct revenue it over-recognized and costs it under-recognized in statements from 2024 through June 30, 2026. LifeMD says the fixes won't touch its cash flow or cash position. It hasn't said how large they are. Results now come Thursday, Nov. 12, at about 4:05 p.m. ET, per its rescheduling release.
Telehealth buyers pay for revenue growth. Until Thursday's numbers come out, we'd treat every growth figure LifeMD has reported since 2024 as in doubt.
The Signal
503A/503B
FDA warns three Chinese API makers tied to U.S. compounding
Compounded drugs start with bulk active ingredient, or API, that a pharmacy buys from a maker. FDA can demand their records without an inspection. A maker that refuses can be cut off at the border. FDA posted three such cases Tuesday. Import records showed Chongqing Qiancan Technology and Tianjin Healthcare Medical Technology named as maker on multiple API shipments meant for compounding in the U.S. Both refused FDA's records requests, per FDA's letter to Chongqing Qiancan and its letter to Tianjin Healthcare. Both went on Import Alert 66-79 in August. A third maker, Nanjing Hanxin, sells APIs for sterile products and compounding. FDA cites quality failures and says one ingredient it listed can't be used in 503A or 503B compounding. FDA redacted every ingredient name. Ask your pharmacy who made its API.
Telehealth
Hims & Hers owes $563 million in deferred deal payments
Hims & Hers' goodwill rose to $1 billion at the end of September from $278 million at the end of 2025, per the balance sheet in its third-quarter release. That's the premium it paid for acquisitions. It owes $563 million in deferred acquisition payments plus $171 million in earn-outs. In nine months it spent $318 million in cash on acquisitions. It booked another $886 million in stock, deferred payments and other non-cash consideration. Hims didn't name the companies it bought in the release. Sellers who take Hims stock or IOUs are betting on Hims.
Medspa
NakedMD to open injectables studios in the Carolinas
NakedMD, a corporate-owned injectables chain backed by Revelstoke Capital Partners, plans to enter North and South Carolina, per Beauty Independent. It had two studios in 2022. Its site now says 40-plus. The menu sticks to injectables, with lip filler from $149. Its chief medical officer says the chain uses "very old-school products." Independent injectors in the Carolinas get a low-price rival.
Telehealth
Tor Health raises its low-dose naltrexone price
Tor Health raised its compounded low-dose naltrexone to $69 a month from $59 on its treatment page. It dropped the subscription option.
Wire
- Comments on HHS's 503A peptide enforcement-discretion policy close Friday, Nov. 13, on Regulations.gov.
- DEA's special-registration rule for telemedicine prescribing is still under White House review on reginfo.gov. The 90-day mark is Monday, Nov. 23, with one 30-day extension allowed.
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.